A Study to Investigate Safety and Effectiveness of CRN09682 in Participants With SST2-Expressing NENs and Other Solid Tumors

ClinicalTrials.gov ID: NCT07129252

Public ClinicalTrials.gov record NCT07129252. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced May 18, 2026, 10:46 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1/2 Dose Escalation Study of CRN09682 With an Expansion Phase in Participants With Progressive Metastatic Somatostatin Receptor Type 2 (SST2)-Expressing Neuroendocrine Neoplasms (NENs) and Other SST2-Expressing Solid Tumors

Study identification

NCT ID: NCT07129252
Recruitment status: Recruiting
Study type: Interventional
Phase: Phase 1, Phase 2
Lead sponsor: Crinetics Pharmaceuticals Inc.; Industry
Enrollment: 150 participants

Conditions and interventions

Conditions

Interventions

CRN09682 Drug

Drug

Eligibility (public fields only)

Age range: 18 Years and older
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Nov 25, 2025
Primary completion: Jul 31, 2027
Completion: Jul 31, 2029
Last update posted: May 10, 2026

2025 – 2029

United States locations

U.S. sites: 20
U.S. states: 13
U.S. cities: 20

Facility	City	State	ZIP	Site status
Crinetics Study Site	Phoenix	Arizona	85054	Recruiting
Crinetics Study Site	Duarte	California	91010	Recruiting
Crinetics Study Site	Newport Beach	California	92663	Recruiting
Crinetics Study Site	Orange	California	92868	Recruiting
Crinetics Study Site	San Francisco	California	60637	Recruiting
Crinetics Study Site	Denver	Colorado	80218	Recruiting
Crinetics Study Site	New Haven	Connecticut	48201	Recruiting
Crinetics Study Site	Atlanta	Georgia	30322	Recruiting
Crinetics Study Site	Lexington	Kentucky	40536	Recruiting
Crinetics Study Site	Metairie	Louisiana	70006	Recruiting
Crinetics Study Site	Detroit	Michigan	48201	Recruiting
Crinetics Study Site	Grand Rapids	Michigan	49503	Recruiting
Crinetics Study Site	Rochester	Minnesota	53905	Recruiting
Crinetics Study Site	Philadelphia	Pennsylvania	19111	Recruiting
Crinetics Study Site	Austin	Texas	78758	Recruiting
Crinetics Study Site	Houston	Texas	70030	Recruiting
Crinetics Study Site	Irving	Texas	75039	Recruiting
Crinetics Study Site	Salt Lake City	Utah	84112	Recruiting
Crinetics Study Site	Charlottesville	Virginia	22908	Recruiting
Crinetics Study Site	Fairfax	Virginia	22031	Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 4 non-U.S. sites.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT07129252, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted May 10, 2026 · Synced May 18, 2026

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT07129252 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →